Literature DB >> 17184953

Therapeutic drug monitoring of tacrolimus with the dried blood spot method.

K Hoogtanders1, J van der Heijden, M Christiaans, P Edelbroek, J P van Hooff, L M L Stolk.   

Abstract

In a preliminary investigation an assay for tacrolimus based on fingerprick sampling and consecutive application as a blood spot on sampling paper has been developed. The dried blood spot was analysed by HPLC-tandem mass spectrometry. The validated range was 1-30 microg/l. Intra- and inter-assay variability for precision and accuracy was <7.5% and 15%, respectively. Tacrolimus concentrations of 24 stable out patients were compared after both blood spot sampling and conventional venous sampling. Method agreement was investigated with the methods of Passing and Bablok and Bland Altman and proved suitable for clinical use. The dried blood spot method for tacrolimus seems promising for patient monitoring.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17184953     DOI: 10.1016/j.jpba.2006.11.023

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  19 in total

1.  Use of dried blood spots in drug development: pharmacokinetic considerations.

Authors:  Malcolm Rowland; Gary T Emmons
Journal:  AAPS J       Date:  2010-04-10       Impact factor: 4.009

2.  Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers.

Authors:  Frank Stifft; Floris Vanmolkot; Ingrid Scheffers; Luc van Bortel; Cees Neef; Maarten Christiaans
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

3.  A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts.

Authors:  Frank Stifft; Franciscus Vandermeer; Cees Neef; Sander van Kuijk; Maarten H L Christiaans
Journal:  Eur J Clin Pharmacol       Date:  2020-02-04       Impact factor: 2.953

4.  Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.

Authors:  Teresa L Parsons; Mark A Marzinke; Thuy Hoang; Erin Bliven-Sizemore; Marc Weiner; William R Mac Kenzie; Susan E Dorman; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

5.  Analysis of tacrolimus and creatinine from a single dried blood spot using liquid chromatography tandem mass spectrometry.

Authors:  Dennis R Koop; Lisa A Bleyle; Myrna Munar; Ganesh Cherala; Amira Al-Uzri
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-03-04       Impact factor: 3.205

Review 6.  Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS.

Authors:  Mwlod Ghareeb; Fatemeh Akhlaghi
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

7.  Predictability of Capillary Blood Spot Toward Venous Whole Blood Sampling for Therapeutic Drug Monitoring of Tacrolimus in Solid Organ Transplant Recipients.

Authors:  Jaryd Gallant; Jenny Wichart; Tony K L Kiang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

8.  Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS.

Authors:  Touraj Shokati; Nicholas Bodenberger; Holly Gadpaille; Björn Schniedewind; Alexander A Vinks; Wenlei Jiang; Rita R Alloway; Uwe Christians
Journal:  J Vis Exp       Date:  2015-11-08       Impact factor: 1.355

Review 9.  Emerging trends in paper spray mass spectrometry: Microsampling, storage, direct analysis, and applications.

Authors:  Benjamin S Frey; Deidre E Damon; Abraham K Badu-Tawiah
Journal:  Mass Spectrom Rev       Date:  2019-09-06       Impact factor: 10.946

Review 10.  Therapeutic drug monitoring by dried blood spot: progress to date and future directions.

Authors:  Abraham J Wilhelm; Jeroen C G den Burger; Eleonora L Swart
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.